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Abstract
Background: Cancer cells possess unique metabolic phenotypes that are determined by their underlying
oncogenic pathways. Activation of the PI3K/Akt/mTOR signaling cascade promotes glycolysis and leads to glucose-
dependence in tumors. In particular, cells with constitutive mTORC1 activity secondary to the loss of TSC1/TSC2
function are prone to undergo apoptosis upon glucose withdrawal in vitro, but this concept has not been tested in
vivo. This study examines the effects of restricting glucose metabolism by pharmacologic and dietary means in a
tuberous sclerosis complex (TSC) tumor xenograft model.
Results: Tumor-bearing mice were randomly assigned to receive unrestricted carbohydrate-free ("Carb-free”)o r
Western-style diet in the absence or presence of 2-deoxyglucose (2-DG) in one of four treatment groups. After 14
weeks, tumor sizes were significantly different among the four treatment groups with those receiving 2-DG having
the smallest tumors. Unexpectedly, the “Carb-free” diet was associated with the largest tumors but they remained
responsive to 2-DG. PET imaging showed significant treatment-related changes in tumor
18fluorodeoxyglucose-
uptake but the standard uptake values did not correlate with tumor size. Alternative energy substrates such as
ketone bodies and monounsaturated oleic acid supported the growth of the Tsc2-/- cells in vitro, whereas
saturated palmitic acid was toxic. Correspondingly, tumors in the high-fat, “Carb-free” group showed greater
necrosis and liquefaction that contributed to their larger sizes. In contrast, 2-DG treatment significantly reduced
tumor cell proliferation, increased metabolic stress (i.e., ketonemia) and AMPK activity, whereas rapamycin primarily
reduced cell size.
Conclusions: Our data support the concept of glycolytic inhibition as a therapeutic approach in TSC whereas
dietary withdrawal of carbohydrates was not effective.
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Background
Tuberous sclerosis is an autosomal dominant disorder
characterized by multiple benign hamartomas and neo-
plasms caused by the disruption of a pair of tumor sup-
pressor genes, TSC1 and TSC2, which encode for
hamartin and tuberin, respectively [1]. Mutations and epi-
genetic silencing of these genes have been reported in
sporadic human cancers including epithelial tumors of the
bladder, liver, and oral cavity as well as PEComas [2-6].
The TSC1 and TSC2 proteins negatively regulate mTOR
Complex 1 (mTORC1) by inhibiting Rheb activity [7].
Consequently, mTORC1 is constitutively activated in cells
lacking TSC1 or TSC2. These findings led to the use of
rapamycin and its analogs in the treatment of TSC and
related disorders [8-11]. The effect of rapamycin is cyto-
static, and tumors re-grow upon cessation of treatment.
Long-term rapamycin can cause significant side effects,
thus alternative approaches are being investigated.
Oncogenic pathways such as PI3K/Akt and Myc pro-
mote aerobic glycolysis and glutaminolysis, respectively, to
provide adequate supplies of ATP and substrates for
macromolecular synthesis [12-15]. The dependence of
tumor growth on these metabolic events provides a basis
for metabolic intervention as a strategy for controlling
tumors [16]. In this study, we examined the in vivo role of
glucose deprivation in TSC-related tumors. Cells lacking
hamartin or tuberin are prone to undergo apoptosis under
low-glucose condition [17,18]. mTORC1 enhances aerobic
glycolysis and lactate production via up-regulation of
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insulin-stimulated glucose uptake secondary to Glut4 mis-
localization [20]. Pathology associated with TSC such as
angiomyolipoma and lymphangioleiomyomatosis display
low FDG uptake on PET imaging despite increased glyco-
lytic activity [20,21]. The imbalance between energy supply
and demand presents a rationale for targeting glucose
metabolism to control mTORC1-mediated tumorigenesis.
Two common approaches to limit glucose metabolism
in tumors include utilization of glycolytic inhibitors and
dietary restriction. Compounds such as 2-deoxyglucose
(2-DG) reduce cellular ATP levels and promote apoptosis
especially in cells with mitochondrial respiration defects
or under hypoxic condition [22,23]. Early clinical experi-
ence suggests that 2-DG is safe up to a dose of 250 mg/
kg [24], but efficacy has not been well documented. Diet-
ary restriction of glucose/carbohydrate (e.g., Atkins-type
diets) leads to relative hypoglycemia, hypoinsulinemia
and ketonemia in humans [25]. Ketogenesis is an ancient
pathway of metabolic adaptation exploited when an
organism experiences protracted energy stress [26]. Criti-
cal tissues such as the brain and kidney can efficiently
metabolize ketone bodies, but it is unclear if tumor cells
exhibit such adaptation.
Here, we studied the effects of 2-DG and a carbohy-
drate-free ("Carb-free”) diet on the growth of mTORC1-
dependent tumors using a Tsc2-/- xenograft model. The
inhibition of glycolysis using 2-DG resulted in reduced cell
proliferation and suppressed tumor growth, thus confirm-
ing the sensitivity of TSC-related tumors to metabolic
intervention. On the other hand, the “Carb-free” diet failed
to promote ketogenesis and led to increased tumor size
d e s p i t er e d u c t i o ni nb o d yw e i g h t s .O u rs t u d yh i g h l i g h t s
the differential effects of glycolytic inhibition and dietary
glucose deprivation in modulating tumor metabolism and
growth.
Results
Sensitivity of Tsc2-/- cells to 2-DG
Our Tsc2-null tumor xenograft model utilizes tumorigenic
LEF2 cells derived from an Eker rat renal tumor [27].
Following low glucose condition (i.e., 2 mM) for 48 hours,
a greater proportion of the LEF2 cells died compared with
wild-type rat kidney, RK3E, cells (Figure 1A). These results
are similar to the findings reported by Inoki et al. [17]. We
also tested the effects of 2-deoxyglucose (2-DG) in vitro by
exposing cells to a low concentration of 2-DG (4 mM) to
mimic a clinically achievable concentration under low- (2
mM) and high- (25 mM) glucose concentrations. Figure
1B shows that a reduction of glucose concentration from
25 mM to 2 mM for 6 hours significantly decreased cell
viability of both wild-type and mutant cells although the
effects were greater in the Tsc2-/- cells. The addition of
2-DG accentuated cell death under low-, but not high-,
glucose condition such that maximal cell death was
achieved in the LEF2 cells when exposed to 2-DG+low-
glucose medium. Correspondingly, cellular ATP levels
decreased with diminished glucose concentration and 2-
DG in an additive manner, and this trend correlated with
increased cell death (Figure 1C). Baseline ATP levels were
significantly higher in the Tsc2-mutant cells, which is con-
sistent with an increased rate of metabolism secondary to
mTORC1 activation [19]. The reduction in cellular ATP
levels in the LEF2 cells under ‘glucose-limiting’ conditions
was accompanied by an increase in AMPK(Thr172) phos-
phorylation that was most pronounced under low-glucose
+2-DG conditions (Figure 1D). The activation of AMPK
was associated with a reduction in p62 expression indica-
tive of autophagy secondary to bioenergetic stress. Wild-
type RK3E cells had higher baseline AMPK activity and
did not change significantly following ‘glucose-restriction’.
Together, the Tsc2-/- cells were sensitive to glucose
restriction and 2-DG in an additive manner.
“Glucose restriction” on Tsc2-/- tumor growth in vivo
Next, we applied these conditions in vivo by treating mice
bearing Tsc2-/- tumors with 2-DG and/or a diet without
carbohydrates. We predicted that the combination of 2-
DG and a “Carb-free” diet would induce a level of energy
stress that would suppress tumor growth. In dose-testing
experiments, the addition of 0.03% 2-DG by weight to the
Western diet led to ~80% of mice with > 20% body weight
loss or death over a 4 week period whereas no mouse suf-
fered this degree of weight loss at 0.02% 2-DG. In terms of
diets, we used a “Carb-free” diet with 67% of the calories
from fat sources, and a ‘control’ Western diet with 40% fat
and 44% carbohydrate as energy (Table 1). Eight-week-old
SCID mice were randomly assigned to one of four treat-
ments (n = 10/group): Western diet, Western diet + 2-DG
(0.02% wt), “Carb-free” diet, or “Carb-free” diet + 2-DG
(0.02% wt). After 4 days of acclimatization to the diets,
each mouse was inoculated subcutaneously with 3 × 10
6
LEF2 cells in the dorsal flank region. Over 14 weeks of
observation, one animal from each group, except the
“Carb-free” diet group, died during this period without
evidence of excessive tumor burden or body weight
change (i.e., random deaths). Three animals in the Wes-
tern+ 2DG group showed significant weight loss over the
experimental period requiring early termination between
10-11 weeks. The remaining 6 mice in the Western+2DG
group had body weights that were similar to the other
groups at the end of 14 weeks (Figure 2A). The “carb-free”
diet also reduced body weight compared to the Western
diet (Figure 2A).
At time of sacrifice, tumor sizes were significantly differ-
ent among the 4 groups (ANOVA, p < 0.05) (Figure 2B).
In pair-wise comparisons, tumor sizes of the Western
+2DG and the ‘Carb’-free groups were significantly
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Page 2 of 15Figure 1 Effects of 2-DG on LEF2 cells. A) Wild-type RK3E and Tsc2-/- LEF2 cells were grown in 10%FBS DMEM with 2 mM glucose. Left: Phase
contrast photomicrographs of cells after 2 days. Magnification 10×. Right: Immunoblot of cell lysates showing expression of cleaved PARP and a-
tubulin at indicated times. Effects of glucose concentration and 2-DG (4 mM) for 6 hours on B) cell viability as determined by Annexin V/PI flow
cytometric analyses, C) cellular ATP levels (Luminescence assay, PerkinElmer), error bars represent SEM. *, p < 0.05, and D) AMPK phosphorylation
and p62 expression by Western blotting. The relative expression of these proteins were analyzed by densitometry, and the numbers under the
blots indicate the ratio of band intensities (Image J) between p-AMPK:total AMPK and p62:a-tubulin. The densitometry results are also shown in
graphical form on the right. Arrows indicate the most significant changes.
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Page 3 of 15different (p < 0.05) while the 2-DG-treated tumors showed
strong trends towards smaller size compared to each of the
respective diets (p = 0.06) (Figure 2B). Tumor size at the
end of 14 weeks and growth rate of tumors were highest in
the “Carb-free” group (Figure 2B, C). Analyses of variance
did not reveal a significant ‘interaction’ between the two
treatments (i.e., 2-DG and diet). Thus, our initial hypoth-
esis of superior tumor control through the combination of
glycolytic inhibition and carbohydrate restriction is not
supported by the data. Instead, we found that 2-DG sup-
pressed tumor growth regardless of diet composition.
Unexpectedly, carbohydrate restriction led to a promotion
in tumor size despite a loss in overall body weight.
Influence of diet and 2-DG on tumor FDG uptake
Recognizing that the prescribed treatments may impact
tumor glucose metabolism, we performed FDG-PET on a
subset of the 12 mice (3 per group) bearing tumors of suffi-
cient size (i.e., > 5 mm) for detection with PET imaging.
Following an overnight fast, mice were given 200 μCi of
18FDG intravenously and scanned after a 45-minute uptake
period. FDG activity was normalized to body weight and
time of FDG injection and expressed as standard uptake
value (SUV). Figure 2E illustrates representative PET
images from each of the 4 treatments showing significant
heterogeneity. We used the maximal SUV value within
each tumor to indicate the metabolic activity of the lesions.
The mean SUVmax of the LEF2 tumors were significantly
different among the 4 groups with the highest values found
in the Western diet group and the lowest in the Carb-free
+ 2-DG group (Figure 2D). While carbohydrate restriction
and 2-DG reduced FDG uptake, SUVmax did not correlate
with tumor size (compare Figures 2B with2D). The para-
doxical increase in tumor size with reduced tumor SUVmax
in the “Carb-free” group suggests the possibility of alterna-
tive energy sources besides glucose that were utilized by
the Tsc2-/- tumor cells.
Ketone bodies support Tsc2-/- cell growth in vitro
Diets devoid of carbohydrate may lead to an imbalance
between b-oxidation of fatty acids and carbohydrate meta-
bolism resulting in ketogenesis [26]. To examine the
effects of ketone bodies on LEF2 cells, we supplemented
the low-glucose (2 mM) culture media with either acetoa-
cetate (AA, 1 mg/ml) or b-hydroxybutyrate (HOB, 2.5 mg/
ml). After 1 day in culture, both LEF2 and RK3E cells
showed greater confluence compared to cells grown in 2
mM glucose alone (Figure 3A). Using trypan blue exclu-
sion assay, the proportion of non-viable LEF2 cells was
moderately reduced in the presence of ketone bodies
(Figure 3B) whereas MTT absorbance remained relatively
constant (Figure 3C). b-hydroxybutyrate supplementation
was accompanied by an increase in ATP levels in the wild-
type cells but had little effect in the LEF2 cells (Figure 3D).
To assess the relevance of these findings in vivo,w e
measured serum b-hydroxybutyrate levels after 14 weeks
of treatments. Contrary to expectation, the “Carb-free”
diet did not induce ketogenesis but rather, had the low-
est average b-hydroxybutyrate and highest glucose levels
(Figure 4A, B) while serum triglyceride trended lower
(Figure 4D) and insulin level remained unchanged
(Figure 4C). On the other hand, those receiving Western
diet + 2-DG had the highest b-hydroxybutyrate and low-
est glucose levels. To confirm that the lack of ketonemia
in the “Carb-free” fed animals was not due to systemic
adaptation following chronic exposure, we conducted a
short-term experiment (e.g., 4 days) using the same
treatment protocol. The ‘acute’ changes in serum glu-
cose and b-hydroxybutyrate paralleled the trends found
in the long-term experiment (Figure 4). Again, the
“Western+2-DG” diet induced the largest metabolic
changes in terms of hypoglycemia and ketonemia. These
observations are consistent with the significant weight
loss associated with “Western+2-DG” treatment. Our
data also indicate that neither acute nor chronic inges-
tion of the carbohydrate-free diet was sufficient to
induce ketogenesis in mice. Although the Tsc2-null cells
can adapt to using ketone bodies in vitro to support cell
Table 1 Composition of the Western and “Carb-free”
diets*
Western “Carb-free”
Energy (kcal/g)
Protein 16.1% 33.2%
Fat 39.7% 66.8%
Carbohydrates 44.2% 0%
Ingredients (%)
Corn starch 31.2 0
Casein 19.7 48.1
Dextrin 10.4 0
Sucrose 7.9 0
Vegetable Shortening 6.1 11.8
Milk fat 6.1 11.8
Lard 6.1 11.8
AIN93G Mineral mix/fiber 4.0 4.7
Inulin 2.5 2.9
Powdered Cellulose 2.5 2.9
Soybean Oil 1.3 2.5
AIN93 Vitamin mix/fiber 1.2 1.3
Corn Oil 0.5 1.1
L-Cystine 0.3 0.7
Choline bitartrate 0.2 0.2
Cholesterol 0.1 0.2
*Source: www.testdiet.com
Western: AIN-93G Western diet (5TJN), “Carb-free": AIN-93G Ketogenic diet
(5TJR))
Jiang et al. Cell & Bioscience 2011, 1:34
http://www.cellandbioscience.com/content/1/1/34
Page 4 of 15Figure 2 Effects of 2-DG and diets on LEF2 tumor xenografts. Eight-week old SCID mice were inoculated with 3 × 10
6 LEF2 cells
subcutaneously and monitored for 14 weeks under 4 treatment conditions: Western diet, Western diet + 2-DG (0.02%), Carbohydrate-free diet,
and Carbohydrate free diet + 2-DG (0.02%). A) Scatter plot of body weights of mice at the end of 14 weeks of treatments. Note that 3 animals
in the “Western+2DG” group were sacrificed prior to week 14 due to significant weight loss (i.e., not included in graph). B) Average tumor sizes
at week 14 expressed as the product of the length and width. C) Tumor growth over the study period for each of the 4 treatment groups
expressed as volume. D) Tumor maximal standard uptake value (SUV) from FDG-PET imaging of 12 mice (3 per group) each with tumor > 5 mm
in diameter. E) Examples of FDG-PET coronal images with flank tumors outlined by dotted lines. For graphs, error bars represent SEM. *, p < 0.05;
◆, p = 0.06.
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Page 5 of 15survival, the accelerated tumor growth in the “Carb-free”
group was not associated with ketonemia.
Role of fatty acids in the “Carb-free"-fed tumors
Since the “Carb-free” diet is composed primarily of fat
(i.e., 67%), of which 40% is saturated fatty acids, its
absorption from the intestine provides a direct source of
fatty acids that can serve as energy substrates. To
examine the effects of fatty acids on LEF2 cells, we incu-
bated cells with monounsaturated oleic acid and/or
saturated palmitic acid in the presence of 25 mM glu-
cose for 24 hours. Exposure to oleic acid led to the
accumulation of cytoplasmic vesicles and cell prolifera-
tion (Figure 5A, B). On the other hand, palmitic acid
induced cell death in 63% and 94% of LEF2 and RK3E
cells, respectively and reduced cell proliferation of RK3E
Figure 3 Influence of ketone bodies on LEF2 cells. A) Appearance of cells under phase contrast microscopy following 2 days of exposure to
acetoacetate (AA, 1 mg/ml), b-hydroxybutyrate (HOB, 2.5 mg/ml), or vehicle control under low-glucose (2 mM) condition. Magnification 10×.
Effects of ketone bodies on B) cell death as determined by trypan blue exclusion assay, C) proliferation (MTT assay) and D) ATP levels. For
graphs, error bars represent SEM. *, p < 0.05.
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Page 6 of 15Figure 4 Systemic metabolic responses to diets and 2-DG. Sera obtained at sacrifice in fasted animals was analyzed for A) glucose, B) b-
hydroxybutyrate (BHOB), C) insulin and D) triglyceride (TG). Chronic diet (black bars) indicates those that were treated for 14 weeks. Acute diet
(open bars) indicates treatments for 4 days. Error bars represent SEM. *, p < 0.05.
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Page 7 of 15Figure 5 Effects of fatty acids on LEF2 cells. A) Appearance of cells 24 hrs following exposure to oleic acid (OA, 1 mM), palmitic acid (PA, 1
mM), both (OA+PA, 3 mM at 2:1 ratio) or vehicle control. Magnification 10×. Inserts represent higher magnification views showing cytoplasmic
vesicles. B) Assessment of cell viability (Trypan blue exclusion), proliferation (MTT), and ATP levels following 6 hours of fatty acids exposure. C)
Western blot analyses of cell lysates from each of the four treatments blotted for the indicated proteins. a-tubulin serves as a loading control.
For graphs, error bars represent SEM. *, p < 0.05; ◆ indicates p < 0.01 compared to all other groups; O indicates p < 0.05 compared to all other
groups.
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acid to cultures with palmitic acid significantly improved
cell viability. Cellular ATP levels decreased in the pre-
sence of fatty acids, but more so with palmitic acid (Fig-
ure 5B). Corresponding to the reduced energy state,
AMPK and JNK phosphorylation were induced most
prominently by palmitic acid, and this was accompanied
by the expression of cleaved PARP (Figure 5C). There-
fore, monounsaturated oleic acid and saturated palmitic
acid have contrasting effects on cell viability and prolif-
eration. These findings correlate with our in vivo obser-
vation that tumors in the “Carb-free” group showed
increased areas of necrosis and liquefaction (see below).
2-DG reduces tumor proliferation
Histologically, the LEF2 tumor xenografts in the 4 treat-
ment groups shared features of the parent tumor with
large, eosinophilic cells and prominent nucleoli accompa-
nied by abundant tumor vessels (Figure 6A). However,
the larger tumors in the “Carb-free” group had signifi-
cantly more necrotic areas that correlated with a soft tex-
ture on gross examination (Figure 6B). On sectioning,
these tumors contained liquefied, hemorrhagic materials
that correlated with the ‘patchy’ FDG-uptake on PET (see
Figure 2E).
We determined the rate of cell proliferation by counting
the number of cells with nuclear BrdU staining following
in vivo labeling (Figure 6B). With over 1,000 cells counted
for each group, the proportion of BrdU(+) cells was signifi-
cantly reduced with 2-DG treatment (Figure 7A). Tumors
from the Western diet-fed mice had the highest prolifera-
tive rate but this was not significantly different from those
fed “Carb-free” diet. Since the “Carb-free” group with the
largest tumors did not have the highest proliferative rates,
other processes beside cell proliferation may be influen-
cing tumor size. Neither cell size nor tumor CD34+ struc-
tures were significantly different between the treatment
groups (data not shown). Instead, tumors in “Carb-free”
diet group displayed necrosis and liquefaction probably on
the basis of saturated fatty acids. This may have contribu-
ted to the increase in overall tumor size. Nonetheless,
“Carb-free” tumors contained a significant amount of
viable cells since rapamycin effectively reduced the tumor
sizes in the “Carb-free"-diet group to the same extent as
the “Western"-diet group (Figure 7B). Histologically, rapa-
mycin-treated tumors showed significant reduction in cell
size whereas 2-DG primarily decreased proliferation, thus
highlighting differences in anti-tumoral mechanisms
(Figure 7C).
Finally, we compared the relative activities of the Akt/
mTOR and AMPK pathways in LEF2 tumors following the
four treatments. Tumor lysates uniformly showed high
levels of phospho-S6 indicative of mTORC1 activation and
low levels of phospho-Akt secondary to feedback inhibition
[7] with no consistent diet/treatment-related effects (Figure
7D). Thus, the anti-tumoral effects of 2-DG was not sec-
ondary to mTORC1 inhibition. AMPK phosphorylation
was most pronounced following exposure to the “Western
diet+2-DG” treatment in keeping with its associated meta-
bolic stress (e.g., ketonemia) and our in vitro findings (see
Figure 1D, 4). However, this did not correlate with changes
in the levels of phospho-S6, p27, or cyclin D1. Further,
there was no consistent alterations in p62 or phospho-
eIF2a expression in tumor lysates to suggest induction of
autophagy or ER stress, respectively. In contrast, rapamycin
abolished S6 phosphorylation, increased Akt phosphoryla-
tion and reduced p62 expression to an equal extent in
tumors from the “Western” and “Carb-free"-diet groups
(Figure 7E); this is consistent with the known effects of
rapamycin in promoting autophagy [28].
Discussion
We investigated two approaches aimed at restricting glu-
cose metabolism in the treatment of TSC-related tumors.
The rationale of our study is based on the observations
that the loss of TSC1/TSC2 leads to an energy imbalance
caused by mTORC1 hyperactivity that increases energy
demand stemming from macromolecular synthesis and
reduces energy supply as a result of impaired insulin-sti-
mulated glucose uptake [19,20]. Consequently, cells defi-
cient in TSC1 or TSC2 are prone to undergo apoptosis
upon glucose withdrawal or 2-DG treatment [17]. The
combination of low glucose concentration and 2-DG was
more effective in limiting ATP, activating AMPK and
inducing cell death in vitro (Figure 1). When applied to an
in vivo model of Tsc2-null tumor, 2-DG suppressed tumor
growth by reducing cell proliferation whereas a diet free of
carbohydrate resulted in larger tumors with increased
zones of liquefaction. We did not detect an ‘additive’ effect
when the two treatments were given together. These find-
ings indicate that the Tsc2-related tumors are sensitive to
glycolytic inhibition in vivo, but the lack of tumor suppres-
sion following dietary restriction of carbohydrate could be
a reflection of its inability to induce significant hypoglyce-
mia. On the other hand, the increased necrosis in the
“Carb-free” fed tumors was not due to an effect of the diet
on tumor vasculature, ER stress or autophagy since the
tumor expression of CD34, phospho-eIF2a(Ser51) and
p62 were not significantly different among the 4 groups.
The ketogenic diet has been investigated for over two
decades as a treatment for malignant brain tumors
based on the notion that tumor metabolism favors aero-
bic glycolysis (i.e., Warburg effect) whereas tissues of
critical organs such as the brain can utilize ketone
bodies efficiently [29]. In a short-term study, Marsh et
al. reported a synergistic effect of 2-DG and a carbohy-
drate-free diet on inhibiting astrocytoma growth in a
m o u s em o d e l .T h e ya t t r i b u t e dt h eb e n e f i to ft h ed i e tt o
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Page 9 of 15Figure 6 Morphologic appearances of LEF2 tumor xenografts. A) Comparison of parental renal cell tumor from an Eker rat and a LEF2
xenograft. Shown are representative sections of H&E-stained, formalin-fixed tumors. Magnification 400×. B) Representative microscopic
appearances of the LEF2 xenografts at time of sacrifice from each treatment group. Shown are low- (left) and high- (right) magnification views
of the H&E and BrdU staining for each of the 4 treatment groups. Note the hemorrhagic and necrotic zones (arrows) in the Carb-free sample.
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Page 10 of 15Figure 7 Effects of ‘glucose deprivation’ on tumor proliferation, response to rapamycin and signaling. A) Tumor proliferation rates based
on BrdU incorporation. BrdU (50 μg/g) was injected intraperitoneally once daily for two days before sacrifice. Histologic sections were stained
with anti-BrdU antibodies. For each sample, > 1,000 tumor cells were counted to determine the fraction of tumor cells with positive nuclear
BrdU staining. *, p < 0.05. B) Response of the LEF2 tumors to rapamycin treatment (Rapa, 1 mg/kg - 5 days a week for 2 weeks) based on
change in tumor volume. Three mice per group. C) Representative photomicrographs of LEF2 xenografts following 2-DG and rapamycin (Rapa)
treatment. Magnification 400×. Note differences in cell size. D) Immunoblot of representative tumor lysates from the 4 treatment groups (2 each)
showing the expression of the indicated proteins. W, Western diet; CF, carbohydrate-free diet. E) Western blot of tumor lysates from (B) showing
effects of rapamycin on mTORC1 (p-S6), Akt (p-Akt), and autophagic (p62) pathways.
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Page 11 of 15energy restriction resulting in ketogenesis and significant
weight loss [30]. When diet was given without restric-
tion, its composition did not appear to significantly
impact tumor growth in vivo [31]. In our study, mice
receiving the “Carb-free” diet weighed less than the
Western diet group, but the difference was only ~10%,
and the b-hydroxybutyrate levels did not rise signifi-
cantly. Thus, unrestricted “Carb-free” diet per se did not
create a state of metabolic “stress” in mice. In addition
to the lack of caloric restriction, our “Carb-free” diet
contained high protein content that can serve as an
energy source via gluconeogenesis. Mavropoulos et al.
also failed to show a significant anti-tumoral effect of
the no-carbohydrate ketogenic diet compared with a
Western diet in a prostate cancer xenograft model
despite a decrease in serum insulin, IGF-1 and phospho-
Akt levels [32]. Interestingly, the ketogenic diet used in
controlling seizures has been associated with disease
p r o g r e s s i o ni n3o f5h u m a nT S Cp a t i e n t s[ 3 3 ] .
Together, these findings should raise awareness for
more vigilant monitoring of TSC-related pathology in
patients receiving the ketogenic diet for seizure manage-
ment. At present, the effects of caloric restriction in
TSC-related tumors are not known, but we surmise the
possibility that a caloric-restricted diet with reduced glu-
cose (exogenous or endogenous) availability may syner-
gize with 2-DG to limit tumor growth.
Inhibition of glycolysis by 2-DG is currently being tested
in clinical trials. 2-DG causes a depletion of cellular ATP
that leads to the activation of AMPK. In combination with
a Western diet, 2-DG treatment had the most severe
metabolic stress in terms of hypoglycemia and ketogenesis.
Consequently, we encountered a greater degree of toxicity
with 3 of 10 mice experiencing significant weight loss
before the completion of the experiment. This metabolic
consequence was not observed in the mice receiving 2-DG
while fed a “Carb-free” diet. Significant weight loss occurs
when glycolysis is inhibited in which carbohydrate consti-
tutes a significant source of energy as in the Western diet.
When glucose becomes limiting, the body mobilizes fat
stores for energy (i.e., lipolysis) resulting in loss of subcuta-
neous fat and weight, which is what we observed in a sub-
set of the Western+2DG group. In contrast, the “Carb-
free” diet provides abundant fat and protein as energy sub-
strates, thus limiting the severity of weight loss. With
respect to the Western diet+2DG treatment, AMPK
(Thr172) phosphorylation was increased under in vitro
and in vivo conditions, but we did not detect significant
suppression of mTORC1 activity or changes in p27 and
cyclin D1 expression. Therefore, the mechanism of 2-DG
inhibition on cell proliferation in vivo remains undefined.
Compared to rapamycin-treated samples, two distinct pat-
terns of response emerged with 2-DG slowing prolifera-
tion and rapamycin reducing cell size. However, it is
unlikely that the combination of 2-DG and rapamycin
would be beneficial since the effects of mTORC1 inhibi-
tion would neutralize the glucose-dependence of the Tsc2-
null cells. Indeed, Inoki et al. have shown that rapamycin
and re-expression of Tsc2 in LEF2 cells rescued them
from apoptosis under low-glucose condition [17].
Besides glucose, we found that ketone bodies can be uti-
lized by cells in vitro to promote survival and growth
although these effects were mild (Figure 3). In contrast,
Fine et al. reported that ketone bodies inhibit cell growth
by reducing ATP concentration in tumor cells that over-
express UCP2 [34]. We also showed that cell proliferation
can be augmented by oleic acids in culture despite a
reduction in cellular ATP, but saturated palmitic acid was
t o x i ct oc e l l s .T h e s ef i n d i n g sa r ei nk e e p i n gw i t ht h o s e
reported by Ricchi et al. in hepatocytes [35]. Considered
together, the Tsc2- tumor cells exhibit metabolic plasticity
beyond their dependence on glycolysis. This may explain
the lack of correlation between FDG uptake and tumor
response. Further, glutamine has also been identified as an
important nutrient in supporting cellular bioenergetics of
the Tsc2-null cells [18]. In future studies, targeting multi-
ple metabolic pathways may be considered to maximize
tumor control while minimizing toxicity.
Conclusions
Our study provides the first in vivo evidence demonstrat-
ing anti-tumoral effects of glycolytic inhibition in TSC2-
related tumors. The predominant effect of 2-DG was to
inhibit cell proliferation in contrast to the effect of rapa-
mycin on cell size. A diet free of carbohydrate without
caloric restriction was not effective in controlling TSC2-
tumor growth, but changed the consistency of the tumors
by inducing necrosis.
Methods
Cells and reagents
LEF2 cells were derived from an Eker rat renal tumor
(Tsc2-/-), and the wild-type rat kidney-derived cells,
RK3E, were purchased from ATCC. Both were cultured
in DMEM/F12 medium containing 10% FBS fetal bovine
serum (FBS), 100 units/ml penicillin G and 100 μg/ml
streptomycin sulfate at 37°C in a humidified 5% CO2
incubator. Antibodies were purchased from the follow-
ing sources: anti-BrdU (Dako), anti-CD34 (Cedarlane,
Burlington, NC), anti-p62 and anti-a-tubulin (Sigma, St.
Louis, MO). All remaining antibodies (anti-AMPK, anti-
phospho-AMPK(Thr172), anti-S6, anti-phospho-S6,
anti-p27, anti-cyclin D, anti-eIF2a,a n t i - A k t ,a n t i - p h o s -
pho-Akt, anti-cleaved PARP, and anti-cleaved-caspase 3)
were from Cell Signaling (Danvers, MA). 2-deoxyglu-
cose, oleic and palmitic acids were purchased from
Sigma (St. Louis, MO). Rapamycin were obtained from
EMD Biosciences (San Diego, CA).
Jiang et al. Cell & Bioscience 2011, 1:34
http://www.cellandbioscience.com/content/1/1/34
Page 12 of 15Xenograft model of Tsc2-null tumor
Young (5-6 weeks), male, NOD.CB17-prkdcscid/J mice
w e r ep u r c h a s e df r o mJ A Xa n df e dr e g u l a rc h o wf o r2 - 3
weeks. At 8 weeks of age, animals were randomly allo-
cated to 4 treatment groups: Western diet, Western
+0.02% 2-DG, ‘Carb-free’ diet, ‘Carb-free’+0.02% 2-DG.
The diets with and without 2-DG were prepared and
purchased from Animal Specialties (Hubbard, OR).
After 4 days on treatment, 3 × 10
6 LEF2 cells were
injected subcutaneously in the flank region of the mice.
Animals were monitored for tumor growth and general
health for 14 weeks. After an overnight fast, mice were
sacrificed, tumors and sera were collected for analyses.
F o ras u b s e to f1 2a n i m a l s ,F D G - P E Tw a sp e r f o r m e d
(see below) and BrdU (50 μg/g) was injected intra-peri-
toneally once daily for two days before sacrifice. All
work related to animals was in accordance with a proto-
col approved by the Institutional Animal Care Commit-
tee, University of Washington, Seattle.
FDG-PET imaging
Following an overnight fast, mice were anesthetized using
isoflurane and given a retro-orbital injection of FDG (200
μCi). Mice were kept warm and anesthetized during a
45-minute uptake period. Following this, mice were
imaged for 20 minutes on a Siemens Inveon Dedicated
PET system at the micro-PET imaging facility (University
of Washington). A transmission scan was taken of each
mouse after the emission study. Images were recon-
structed using the manufacturer supplied 3D OSEM
MAP image reconstruction. Data were collected with
both random, scatter and attenuation correction. A Beta
smoothing parameter of 0.1 was used. The maximum
uptake value for each tumor was captured from the
reconstructed images by stepping through the tumor and
measuring the maximum activity (nCi/cc) in all hotpots
and was normalized to body weight and time of FDG
injection (to account for decay) in order to calculate the
standard uptake value (SUV).
Trypan Blue Exclusion Assay
Quantification of viable cells was performed using the
trypan blue exclusion method. In brief, cells were har-
vested and collected following trypsin detachment and
centrifugation. Cells were rinsed with PBS and then
resuspended in 1 ml of PBS. A 10-μl aliquot of cell sus-
pension was incubated with 10 μl0 . 4 %t r y p a nb l u es t a i n
(Invitrogen/Gibco) solution for 5 minutes at room tem-
perature. Viable and nonviable cells based on absence
and presence of intracellular dye, respectively, were
counted by hemacytometer. Results represent the num-
ber of nonviable cells divided by the total number of cells
counted and are expressed as percentages.
Flow Cytometric Analyses
Cell apoptosis was measured by flow cytometry using
the Annexin V kit (AbD Serotec, Raleigh, NC). In brief,
RK3E and LEF2 cells were detached following treatment
with 0.05% trypsin-EDTA for 10 minutes at 37°C,
washed with PBS, pelleted by centrifugation, resus-
pended with pre-diluted binding buffer, and stained
with Annexin V-FITC for 10 minutes in the dark at
room temperature. Cells were washed and resuspended
in binding buffer with Propidium lodide solution and
analyzed by flow cytometry.
ATP level measurement
Cells were seeded on plates with 10% FBS with DMEM/
F12 medium for overnight, then washed with PBS and
replaced with 10% dialyzed FBS DMEM with 2 mM glu-
cose, 1 mM HEPES. After 1 day in culture medium, cells
were treated with 4 mM 2-Deoxyglucose, 1 mg/ml acetoa-
cetate, or 2.5 mg/ml b-hydroxybutyrate for 6 hours. ATP
levels were measured using a Luminescence ATP detec-
tion assay system (PerkinElmer, MA). Briefly, cells were
lysed for 5 minutes with supplied lysis buffer in an orbital
shaker at 700 rpm, then ATP detection substrate solution
was added to the wells and agitated for 5 minutes. Plates
were left in the dark for 10 minutes and luminescence was
measured using a Molecular Devices Spectra Max M2
(Sunnyvale CA).
For fatty acid experiments, oleic acid-BSA and palmitic
acid-BSA solutions were pre-made (2 moles of FFA to 1
mole BSA). Cells were washed with PBS and cultured in
10% charcoal striped FBS phenol-free DMEM with 1 mM
Oleic acid-BSA, 1 mM palmitic acid-BSA, or 2 to 1 molar
of oleic acid/palmitic acid (3 mM) for 24 hours.
MTT assay
Cells were grown on 24-well plates in 10% FBS DMEM/
F12, treated with ketone bodies (1 mg/ml acetoacetate or
2.5 mg/ml b-hydroxybutyrate for 24 hours) or FFA (1 mM
oleic acid, 1 mM palmitic acid or 3 mM oleic acid + pal-
mitic acid for 24 hours) followed by MTT proliferation
assay. Briefly, 100 μl of 5 mg/ml MTT was added to each
well and incubated for 3.5 hours. 750 μlo fM T Ts o l v e n t
(4 mM HCl, 0.1% Nondet P-40 in isopropanol) was added
to each well and agitated for 15 minutes. Optical density
was read at 600 nm using a Packard Spectracount micro-
plate reader (PerkinElmer, Inc., Waltham, MA).
Serum biochemistry
Blood was extracted via cardiac puncture immediately
after sacrifice. Blood was spun for 15 minutes at 3000 rpm
at 4°C. Plasma was analyzed for glucose, insulin, b-hydro-
xybutyrate, and triglycerides. Plasma glucose levels were
measured colorimetrically using the glucose oxidase
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Page 13 of 15reagent (Pointe Scientific, Canton, MI). Plasma insulin
levels were measured using the Linco ELISA (Millipore,
Billerica, MA). b-hydroxybutyrate in plasma was measured
using the KetoSite b-hydroxybutyrate dehydrogenase assay
according to the manufacturer’s instructions (Stanbio
Laboratory, Boerne, TX). Plasma triglycerides were quanti-
fied via the Wako L-Type TG M colorimetric assay (Wako
Diagnostics, Richmond, VA).
Histology and immunohistochemistry
Portions of tumor were fixed in either neutral buffered
formalin for routine histology and immunohistochemistry
(IHC) or in methacarn (60% methanol, 30% chloroform,
and 10% acetic acid) for bromo-deoxyuridine (BrdU) label-
ing. After fixation, tissue was embedded in paraffin. For
routine histological analysis, 5-μm sections were cut from
paraffin-embedded blocks and sections were deparaffi-
nized, rehydrated, and washed before staining with hema-
toxylin QS and eosin (Vector Laboratories, Burlingame,
CA) and mounted with Permount (Fischer Scientific,
Santa Clara, CA). For CD34 staining, sections were depar-
affinized, rehydrated, and washed with phosphate-buffered
saline. After antigen retrieval in 0.1 M sodium citrate (pH
6.0) and quenching of endogenous peroxidase activity with
3% H2O2, samples were blocked with 5% normal horse
serum (NHS) before incubation with primary antibodies
overnight at 4°C. Negative controls were treated with 5%
NHS without primary antibodies. Staining was detected
using the Elite Vectastain ABC kit (Vector laboratories,
Burlingame, CA) according to the manufacturers instruc-
tions. BrdU IHC was performed as described above with
the following modifications: endogenous peroxidase activ-
ity was quenched with 0.3% H2O2/Methanol for 10 min-
utes and antigen retrieval consisted of trypsin digestion
(1 mg/ml trypsin for 10 min at room temperature), fol-
lowed by incubation in 2.5 M HCl for 10 min at 37°C.
Mouse anti-BrdU diluted 1:40 was used as the primary
antibody (Dako, Carpinteria, CA, USA).
Immunoblot analyses
Cells and tumor tissues were homogenized in ice-cold
radioummunoprecipitation (RIPA) buffer (1% Nonidet
P-40, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl,
10 mM Tris (pH 7.2), 0.025 M b-glycophosphate (pH
7.2), 2 mM EDTA, and 50 mM sodium fluoride) with
protease and kinase inhibitors (0.05 mM AEBSF, 10 μg/
ml aprotinin, 10 μg/ml pepstatin, 1 mM orthovanadate,
10 μg/ml leupeptin, 1 mM microcystin LR). The protein
concentration was measured using the BCA Protein
Assay (Pierce, Rockford, IL). Equal amounts of protein
were separated by SDS-PAGE, transferred to Immobilin-
P membranes (Millipore, Bedford, MA) and blotted with
antibodies according to manufacturer recommendations.
Statistical analyses
Comparisons between two groups were analyzed using
the Student t-test. For multi-group comparisons, analy-
sis of variance (ANOVA) was used.
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